Edition:
United Kingdom

Vanda Pharmaceuticals Inc (VNDA.OQ)

VNDA.OQ on NASDAQ Stock Exchange Global Market

14.35USD
15 Dec 2017
Change (% chg)

$0.30 (+2.14%)
Prev Close
$14.05
Open
$14.05
Day's High
$14.55
Day's Low
$14.05
Volume
831,405
Avg. Vol
158,890
52-wk High
$18.95
52-wk Low
$11.90

Latest Key Developments (Source: Significant Developments)

Vanda receives negative opinion for marketing authorization from the European Medicines Agency
Friday, 10 Nov 2017 

Nov 10 (Reuters) - Vanda Pharmaceuticals Inc ::Vanda receives negative opinion for marketing authorization from the European Medicines Agency on fanaptum™ for the treatment of schizophrenia.Vanda Pharmaceuticals Inc - ‍CHMP re-examined its negative opinion and confirmed refusal of fanaptum MAA​.  Full Article

Vanda Pharmaceuticals posts qtrly ‍net loss of $0.10​/share
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Vanda Pharmaceuticals Inc :Qtrly ‍net loss per share $0.10​.  Full Article

Vanda Pharmaceuticals reached a pricing agreement with the German National Association of Statutory Health Insurance Funds
Wednesday, 18 Oct 2017 

Oct 18 (Reuters) - Vanda Pharmaceuticals Inc :Vanda Pharmaceuticals - On Oct 17, co reached a pricing agreement with the German National Association of Statutory Health Insurance Funds.Vanda Pharmaceuticals - Pricing agreement for treatment of totally blind individuals with sleep-wake disorder with Hetlioz after an arbitration board decision.Vanda Pharmaceuticals - ‍Ex-factory price of Hetlioz in Germany expected to be about eur 69,000/year, effective date of Aug 1, 2017​ - SEC Filing.  Full Article

Vanda says U.S. District Court ruled Roxane Laboratories infringed certain patents
Thursday, 25 Aug 2016 

Vanda Pharmaceuticals Inc :U.S. District Court ruled that Roxane Laboratories infringed U.S. patent nos. RE39,198 and 8,586,610 by submitting to FDA an ANDA.  Full Article

Vanda Pharmaceuticals Q2 loss per share $0.11
Wednesday, 27 Jul 2016 

Vanda Pharmaceuticals Inc : Vanda pharmaceuticals reports second quarter 2016 financial results . Vanda reiterates 2016 net product sales guidance of $143 million to $153 million . Qtrly loss per share $0.11; revenue $36.03 million . Says reiterates its prior 2016 financial guidance . Hetlioz net product sales grew to $17.5 million , fanapt net product sales grew to $18.6 million in q2 2016 .Says year end 2016 cash is expected to be between $123 and $143 million.  Full Article

Vanda says FDA approved NDA for drug to treat schizophrenia in adults
Thursday, 26 May 2016 

Vanda Pharmaceuticals Inc : New approved PI now includes placebo-controlled, long-term study data .Vanda announces FDA approval of the Fanapt supplemental new drug application for maintenance treatment of schizophrenia in adults.  Full Article

BRIEF-Vanda receives negative opinion for marketing authorization from the European Medicines Agency

* Vanda receives negative opinion for marketing authorization from the European Medicines Agency on fanaptum™ for the treatment of schizophrenia